1742PD - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
| Autor: | Daniel, D. 1, Kuchava, V. 2, Bondarenko, I. 3, Ivashchuk, O. 4, Spigel, D. 5, Dasgupta, A. 6, Reddy, S. 7, Melkadze, T. 8, Jaal, J. 9, Kudaba, I. 10, Hart, L. 11, Matitashvili, A. 12, Koynov, K.D. 13, Yang, Z. 14, Wolfe, S.G. 15, Malik, R. 16, Morris, S.R. 17, Antal, J.M. 17, Goldschmidt, J. 18 |
|---|---|
| Zdroj: | In Annals of Oncology October 2019 30 Supplement 5:v713-v713 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|